A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK

Malik, Nabeel; Sheth, Hiten G; Ackerman, Nicola; Davies, Nigel; Mitchell, Suzanne M.

doi:10.1136/bjo.2006.106278

Cited by 20 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study of 25 CHC patients, there was a 16% prevalence of retinopathy on a 3-month eye exam; however, pre-treatment eye exams were not performed [14]. In another recent study that enrolled 40 patients with baseline eye exams, only ten patients showed up for follow-up at 6-9 months limiting conclusion on outcome [15]. Our study is the first to have baseline exams, follow-up exams on therapy and posttherapy exams.…”

Section: Discussionmentioning

confidence: 74%

Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin

et al. 2009

View full text Add to dashboard Cite

The purpose of this study is to evaluate the incidence and outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin. A total of 74 hepatitis C patients with baseline eye exams and eye exams during therapy were included. Retinopathy was defined as development of cotton wool spots and/or intra-retinal hemorrhage. Demographics, hepatitis C viral characteristics, treatment and laboratory data, and eye exam findings were compared in groups with and without retinopathy. Retinopathy developed in 28 (38%), early in therapy. Pre-treatment eye exams did not predict risk of retinopathy. Therapy was continued in all but one; cotton wool spots resolved in 24 of 26. All nine patients with intra-retinal hemorrhage had resolution. No patient had retinopathy-related visual deterioration. Retinopathy is common with peginterferon therapy, but the outcome is favorable. Cessation of therapy for retinopathy is not warranted. Severe visual disturbances and scotomas deserve further evaluation.

show abstract

Section: Discussionmentioning

confidence: 74%

Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin

et al. 2009

View full text Add to dashboard Cite

show abstract

“…PEG-IFN-associated retinopathy has been observed to have similar clinical features and a reported incidence of 16–29.3%, which is somewhat lower than that of IFN-associated retinopathy [17,18,19,20]. In this study, the incidence of retinopathy was identified as 21.73%.…”

Section: Discussionmentioning

confidence: 70%

Pegylated-Interferon-Associated Retinopathy in Chronic Hepatitis Patients

Lim

Shin

2009

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To investigate the clinical features of pegylated-interferon (PEG-IFN)-associated retinopathy in chronic hepatitis patients. Methods: We examined a consecutive case series of 46 patients who were treated with PEG-IFN for chronic hepatitis C or B between October 2007 and September 2008. All patients underwent regular ophthalmologic examinations every 3 weeks during the 6 months after treatment. Results: Ten of the 46 patients (21.73%) developed retinal abnormalities. PEG-IFN-associated retinopathy occurred a mean of 7.25 ± 10.28 weeks after treatment and manifested itself as cotton wool spots and retinal hemorrhages. All patients, except for 1 with a retinal vein occlusion, recovered without cessation of treatment. Conclusions: PEG-IFN-associated retinopathy in chronic hepatitis patients was reversible, and patients recovered without visual complications; however, 1 patient did present with an irreversible visual impairment. This type of retinopathy is usually asymptomatic, and clinicians should closely observe patients for 3 months after treatment.

show abstract

“…Studies by Jain et al (19), Cuthbertson et al (13) and Okuse et al (20) have shown a relatively higher incidence of retinopathy (symptomatic or asymptomatic) ranging from 19% to 64% during treatment with IFN; however Malik et al (21) and Panetta et al (22) showed relatively lower incidence of retinopathy (0% and 3.8%, respectively). Also, the estimated prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy in USA was 28.5% and 4.4% respectively, among persons with diabetes aged 40 years and older.…”

Section: Discussionmentioning

confidence: 97%

Ophthalmological side effects of interferon therapy of chronic hepatitis C

Medhat¹,

Esmat²,

Hamza³

et al. 2016

Hepatobiliary Surg. Nutr.

View full text Add to dashboard Cite

Background: Egypt has one of the highest prevalence of hepatitis C virus (HCV) worldwide.Ophthalmological side effects are recognized complications of interferon (IFN) therapy. This study aimed to evaluate IFN-induced ophthalmological manifestations in patients receiving PEGylated interferon (PEG IFN) and ribavirin (RBV) and to assess the effect of IFN duration, response and systemic risk factors on the severity. Methods:We retrospectively analyzed 100 patients with chronic HCV who were candidates for PEG-IFN and RBV therapy. All patients were subjected to clinical and ophthalmological examination, laboratory investigations, abdominal ultrasound, colored fundus photography and fundus fluorescein angiography, follow up was made at weeks 12, 24, and 48 of treatment.Results: IFN-induced retinopathy had been found in (9/100; 9%), 5 (5/9; 55.5%) of them had bilateral lesions, (3/9; 33.3%) were treatment responders and (6/9; 66.6%) non responders. The time of retinopathy appearance was mainly at W12. Retinopathy was asymptomatic in most of the affected patients (7/9; 77.77%) and reversible, cotton wool spots was the major associated sign. Patients with older age, DM and or HTN, and non-responders to antiviral therapy were associated with more severe retinopathy. Conclusions:Retinopathy is not a rare complication of IFN therapy for chronic HCV infection, but fortunately it's asymptomatic and reversible. Ophthalmological assessment at base-line and at follow up during IFN treatment is very important.

show abstract

A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK

Abstract: In contrast to previous studies in America and south-east Asia, our findings based on a UK cohort suggest that routine ophthalmic screening is not essential for patients with hepatitis C treated with pegylated interferon alpha who have no subjective visual complaints.

Cited by 20 publications

References 14 publications

Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin

Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin

Pegylated-Interferon-Associated Retinopathy in Chronic Hepatitis Patients

Ophthalmological side effects of interferon therapy of chronic hepatitis C

Contact Info

Product

Resources

About